Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director B. Parshall sold 5,000 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $54.73, for a total transaction of $273,650.00. Following the completion of the sale, the director directly owned 5,784 shares of the company’s stock, valued at $316,558.32. This represents a 46.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
B Lynne Parshall also recently made the following trade(s):
- On Tuesday, September 1st, B. Parshall sold 5,000 shares of Cytokinetics stock. The shares were sold at an average price of $71.48, for a total transaction of $357,400.00.
Cytokinetics Price Performance
NASDAQ CYTK traded down $0.03 during trading on Friday, hitting $56.13. 1,013,535 shares of the company’s stock traded hands, compared to its average volume of 1,999,903. The stock has a fifty day moving average of $64.11 and a two-hundred day moving average of $69.78. Cytokinetics, Incorporated has a 12-month low of $53.55 and a 12-month high of $88.31. The firm has a market cap of $7.82 billion, a P/E ratio of -9.29 and a beta of 0.45.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.06. The company had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. During the same quarter in the prior year, the firm posted ($2.55) EPS. The firm’s quarterly revenue was up 2356.5% on a year-over-year basis. As a group, analysts expect that Cytokinetics, Incorporated will post -5.85 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cytokinetics
Hedge funds and other institutional investors have recently modified their holdings of the company. Siren L.L.C. purchased a new position in shares of Cytokinetics during the first quarter valued at about $40,466,000. Hsbc Holdings PLC raised its stake in Cytokinetics by 5,906.5% in the first quarter. Hsbc Holdings PLC now owns 221,999 shares of the biopharmaceutical company’s stock worth $14,632,000 after buying an additional 218,303 shares in the last quarter. Aberdeen Group plc lifted its holdings in Cytokinetics by 182.8% in the third quarter. Aberdeen Group plc now owns 337,728 shares of the biopharmaceutical company’s stock worth $22,260,000 after buying an additional 218,293 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Cytokinetics by 18.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company’s stock worth $90,569,000 after buying an additional 214,060 shares during the period. Finally, Candriam S.C.A. lifted its holdings in Cytokinetics by 39.3% in the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company’s stock worth $40,841,000 after buying an additional 174,320 shares during the period.
Analyst Ratings Changes
CYTK has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $140.00 price target on shares of Cytokinetics in a research report on Monday, October 19th. Needham & Company LLC boosted their price objective on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a research report on Thursday, October 15th. Leerink Partners dropped their price objective on Cytokinetics from $103.00 to $100.00 and set an “outperform” rating for the company in a research note on Thursday, November 5th. Finally, Barclays raised their target price on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $106.67.
Check Out Our Latest Research Report on CYTK
Cytokinetics Company Profile
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Recommended Stories
- Five stocks we like better than Cytokinetics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
